Press Releases
Excerpt from the Press Release: Phase 2a Tolerability and Efficacy Data Supports Further Clinical Development of Samuraciclib in Combination with Fulvestrant in HR+, HER2- Breast Cancer Previously Treated with a CDK4/6 Inhibitor DUBLIN, Ireland and BOSTON, Sept. 16, 2021 (GLOBE NEWSWIRE) — Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today…
Read More
Excerpt from the Press Release: Objective response rate of 33% and median duration of response not reached with 19.4 months median follow-up in PD-L1+ tumors; expands benefit of anti-PD-1 alone Improved responses seen across all histology subgroups including populations of patients unresponsive to other therapies Dr. David O’Malley to present data in an oral presentation…
Read More
Excerpt from the Press Release: SLATE version (v) 1, Gritstone’s “off the-shelf” neoantigen immunotherapy (including KRAS, TP53 mutations), elicited multiple molecular responses and an unconfirmed RECIST radiologic response in patients with NSCLC who had progressed on prior immunotherapy SLATE v2 (a mutant KRAS-focused version), which is optimized for increased immune response, has been administered to…
Read More
– GTB-3650 is a novel molecule based on camelid single-domain antibody technology with advantages that build upon the strong proof-of-concept data from the Company’s first-generation TriKE® program, GTB-3550 – GTB-3650 has shown significantly higher potency than GTB-3550 in preclinical models, as detailed in a recent peer reviewed publication¹ – Company now plans to accelerate its…
Read More
Personalized Therapy Biosimulation Identifies Novel Biomarkers that Predict Drug and Immunotherapy Response in Patients with NSCLC Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced that results from patient stratification studies using the Cellworks Computational…
Read More
Excerpt from the Press Release: – Single dose administration of PLN-74809 achieved αvβ6 target engagement up to 98% in the lungs of IPF patients – All doses achieved target engagement above the threshold for predicted anti-fibrotic activity, with an observed dose-response relationship – PLN-74809 reached highly fibrotic regions of the lung and was bound to αvβ6 in IPF…
Read More
Excerpt from the Press Release: National Health Care Institute of the Netherlands-supported study to evaluate role of the HeartFlow Analysis in reducing unnecessary invasive procedures REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced that physicians at Erasmus MC Hospital (Rotterdam NL) have enrolled the first three patients in the…
Read More
“Clinical development of our bioresorbable sirolimus-eluting scaffold for treating peripheral arterial disease (PAD) is proceeding ahead of schedule and achieving outstanding procedural results,” said Kamal Ramzipoor, CEO of R3 Vascular. Excerpt from the Press Release: MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–R3 Vascular Inc. today reported the successful initiation of its First-in-Human clinical study evaluating the technical and…
Read More
Excerpt from the Press Release: SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral antiviral product candidate, in adult patients with confirmed COVID-19 infection. In preclinical studies, Tempol has been shown to have antiviral, anti-inflammatory and antioxidant activity.…
Read More
Excerpt from the Press Release: First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil. Second site scheduled to start enrolling within one week, with multiple additional sites coming online within one month. SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today the start of enrollment in its Phase 2 efficacy study of human allogeneic adipose-derived mesenchymal…
Read More